Mirus launched RevIT? AAV Enhancer at the end of July 2023. For different AAV serotypes, it can increase the AAV viral genome titer by 1.2-4.9 folds and improve the full capsid rate to a certain extent. Since RevIT can be easily integrated into the existing AAV production process workflow, it is not only compatible with Mirus TransIT-VirusGEN® GMP transfection reagent, but also adaptable to other transfection reagents (such as PEI). This reduces the upstream production cost of AAV viruses, thereby driving down the cost of single-dose gene therapy.

Since the launch of RevIT? AAV Enhancer, Mirus has received testing feedback and positive reviews from global customers, including well-known pharmaceutical companies and CDMO/CROs. From the initial small-scale evaluation stage using shake flasks to the large-scale evaluation stage with 500L bioreactors, from the use of commercialized cells/culture media to self-developed cell/culture media systems, and from focusing only on AAV viral titer to paying attention to the full capsid rate and more other parameters, the performance of RevIT has continuously broken through the limitations of customers' optimization of existing systems. Therefore, it has also brought more product demands, including the launch of larger packaging to meet the needs of large-scale phased evaluation. In addition, to meet the GMP-level requirements for subsequent clinical registration or commercialization stages, Mirus plans to launch a GMP-grade version by the end of 2024 to better serve global customers.

Product Details

· Product Name: RevIT? AAV Enhancer

· Product Specification: 75mL per bottle

· Product SKU: MIR8080

· Launch Date: January 17, 2024

Product Features and Advantages

1. Increases Titer in AAV Viral Production

RevIT? AAV Enhancer steadily increases AAV viral titer by 2-4 folds, compatible with different serotypes, cell culture media, and types of transfection reagents.

2. Cost-Effectiveness

· Reduces the amount of plasmid DNA required, lowering upstream viral production costs while improving the full capsid rate/viral quality.

· Optimizes the production process and reduces the raw materials needed for AAV viral production.

3. Flexibility & Simplicity in Production Process Integration

RevIT? AAV Enhancer can be easily integrated into your existing AAV viral production workflow. Its flexible addition timing and broad compatibility further boost AAV viral titer.

4. Compatibility

It is compatible with single-component-based transfection reagents (e.g., PEI) or Mirus VirusGEN® transfection reagents, with varying degrees of improvement in both AAV viral titer and full capsid rate.

5. Better Performance When Used with TransIT-VirusGEN®

When used in combination with TransIT-VirusGEN®, the overall performance is superior to polymer-based single-component transfection reagents (e.g., PEI).

6. Enables Gene Therapy to Reach More People

Combined with the continuous optimization of upstream and downstream AAV production processes, it paves the way for the next generation of gene therapies to benefit more patients.

For more data and detailed information about RevIT? AAV Enhancer, please refer to the WeChat article "Newly Launched RevIT? AAV Enhancer – Another Powerful Tool to Boost AAV Yield!".

Related Product Information

Founded in 1995, Mirus (USA) is one of the earliest companies in the world to develop high-efficiency and low-toxicity transfection reagents, and also one of the major suppliers of such reagents currently. Recognized as a leader in transfection reagent development, Mirus has achieved many outstanding results that have been globally acknowledged and well-received by a large number of users.

Beijing XMJ Technology Co., Ltd. is the authorized distributor of Mirus in China. Adhering to a professional and rigorous attitude, it has always been committed to providing customers with high-quality products and services. If you are interested in the above-mentioned products, please feel free to send email to info@xmjsci.com or visit the website www.gq44.cn to learn more product information.